Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBay names new board member
Dr Hixson currently serves as chairman of the board of Sequenom, a genetics and molecular diagnostic company. Dr Hixson is also a member of the board of Infinity
Dr Hixson currently serves as chairman of the board of Sequenom, a genetics and molecular diagnostic company. Dr Hixson is also a member of the board of Infinity
As part of the restructuring, Metabasis will focus on the company’s product candidates, MB07811 for the treatment of hyperlipidemia and MB07803 for the treatment of type 2 diabetes,
Mr Bennett has held senior executive positions with several companies in the orthopedic and spine industry including: executive vice president, officer, and board member of NuVasive; early investor,
Financial results for the fourth quarter ended Dec. 31, 2008. Diluted earnings per share, excluding specified items, were $1.06, reflecting 14.0% growth, in line with Abbott’s previous forecast.
This new round of financing was completed through TaiGen Biopharmaceuticals Holdings Limited (Cayman), the parent company of TaiGen Biotechnology. The proceeds are to be used primarily for advancing
Mr Bryant will begin employment with Quidel and join the Quidel board on February 2, 2009. Caren Mason will continue in her current capacity as president and CEO
Scott Gottlieb served as FDA Deputy Commissioner for Medical and Scientific Affairs for the period 2005-2007, and prior to that, from 2003-2004, as senior advisor for medical technology
NanoInk, a technology-based company, is specialized in nanometer-scale manufacturing and applications development for life science and semiconductor industries. The company currently owns 140 patents and applications filed worldwide
The data showed that the new regulatory elements can distinguish the estrogenic pharmacological activity exerted by different compounds and allow for more accurate prediction of specific tissue effect.
Under the companies’ collaboration agreement, Curis will receive a $6 million cash payment from Genentech following initiation of this pivotal trial. Genentech expects to evaluate GDC-0449 in approximately